Your health insurance plan includes a list called a formulary -- a directory of the drugs it covers. If you've ever been stunned at how much it cost you to fill a prescription, it’s possible that ...

CVS Health (NYSE: CVS) today announced updates to its most common commercial template formularies that will expand the use of lower-cost biosimilars across multiple therapeutic categories, including ...

Figuring out how to pay for your prescription medicine is a complicated task. That’s because drug prices and payments are negotiated as part of a package of drugs that are covered by the insurer ...

There are several reasons why considering a switch to a new Medicare Part D plan is a smart move. Since formularies, premiums, deductibles and copays can change every year, a different plan may ...

A real-world report showed the safety and efficacy of zanubrutinib after a community oncology practice replaced ibrutinib with the newer Bruton tyrosine kinase inhibitor on its formulary. A bevy of ...

CVS Caremark will begin offering osteoporosis biosimilars Ospomyv and Stoboclo, as well as generic teriparatide, Bonsity and Tymlos. Like Humira and its biosimilars, Prolia is a specialty drug ...

Laurie Wesolowicz, PharmD, director, pharmacy services clinical, Blue Cross Blue Shield of Michigan (BCBSM), says that clinical evidence and other factors can drive formulary decision-making. Evidence ...

When you opt for a Medicare Part D plan with a low monthly premium, such as $0 or $10, you might think you're saving money. However, these plans often come with restrictive formularies. A formulary is ...

A new class-action lawsuit alleges CVS Caremark unlawfully changed its coverage for popular GLP-1 drug Zepbound. Earlier this year, Caremark revealed that it would remove Eli Lilly's blockbuster drug ...

Over the past two decades the use of step therapy or edits by health insurers has increased significantly. Step therapy, also called step edits, implies that in a given therapeutic class lower cost ...

CVS Caremark will expand the use of lower-cost biosimilars across multiple therapeutic categories effective July 1.